Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function

NCT06608433 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a medication called Rybelsus affects cortisol levels in healthy volunteers to study adrenal function.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, triple-blind study

Participants 22 people

Who can join Ages 18–60 · male only Healthy volunteers accepted.

Timeline Started 2025-01 · est. completion 2025-11

Where 1 site · Switzerland

What this study is testing ClinicalTrials.gov NCT06608433 ↗

Description as written by the study sponsor.

This study aims to investigate the effects of a single dose of the glucagon-like 1 receptor agonist semaglutdie/Rybelsus on the hypothalamo-pituitary-adrenal axis, thus cortisol levels and other stresshormones in healthy males.

Treatments tested

semaglutide Drug

semaglutide/Rybelsus will be administered as a single oral dose
Placebo Drug

Placebo pills will be administered as a single oral dose

Main thing measured	Change in serum cortisol after Rybelsus vs. Placebo
Sponsor	University Hospital, Basel, Switzerland
Conditions studied	Healthy Volunteer Study, HPA, Cortisol Deficiency, Adrenal Insufficiency
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06608433 ↗